Picture of virus under microscope

Research under the microscope...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based.

Explore SIPBS research

Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction

Reid, F. and Fossland, B. and Flapan, A.D. and Duckelmann, C.C. and Hudson, S.A. (2001) Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction. Pharmacy World and Science, 23 (5). pp. 177-178. ISSN 0928-1231

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

The objectives of this study were to validate and implement an audit tool to assess quality and appropriateness of prescribing and to compare inpatient prescribing of secondary prevention in post myocardial infarction patients before and after introduction of a local treatment guideline. The methodology involved a descriptive, non-experimental retrospective case note review comparing patients treated before and after the implementation of a clinical guideline. The analysis of Group1 patients showed that 41% required treatment with an angiotensin converting enzyme inhibitor (ACE-I), and 23% of those did not receive treatment, 20% of patients on ACE-I received sub-therapeutic doses. Seventy-two per cent of patients required treatment with a statin and 22% of those did not receive a statin. Comparison of the treatment of Group 2 showed that, of 53 patients (50% of Group 2) requiring an ACE-I, 100% received it, although 15% received sub-therapeutic doses. Of 69 patients (64% of Group 2) requiring treatment with a statin 96% were prescribed a statin. Improvements in prescribing of β-Blockers, ACE-I and statins were statistically significant. The study found that prescribing improved significantly for β-Blockers, ACE-I and statins after guideline introduction with anticipated benefits to patient outcomes.